Advertisement

Study of adenylyl cyclase-GαS interactions and identification of novel AC ligands

  • Appalaraju Jaggupilli
  • Premnath Dhanaraj
  • Alexander Pritchard
  • John L. Sorensen
  • Shyamala Dakshinamurti
  • Prashen Chelikani
Article

Abstract

Adenylyl cyclases (ACs) are membrane bound enzymes that catalyze the production of cAMP from ATP in response to the activation by G-protein Gαs. Different isoforms of ACs are ubiquitously expressed in different tissues involved in regulatory mechanisms in response to specific stimulants. There are 9 AC isoforms present in humans, with AC5 and AC6 proposed to play a vital role in cardiac functions. The activity of AC6 is sensitive to nitric oxide, such that nitrosylation of the protein might regulate its function. However, the information on structural determinants of nitrosylation in ACs and how they interact with Gαs is limited. Here we used homology modeling to build a molecular model of human AC6 bound to Gαs. Based on this 3D model, we predict the nitrosylation amenable cysteines, and identify potential novel ligands of AC6 using virtual ligand screening. Our model suggests Cys1004 in AC6 (subunit C2) and Cys174 in Gαs present at the AC-Gαs interface as the possible residues that might undergo reversible nitrosylation. Docking analysis predicted novel ligands of AC6 that include forskolin-based compounds and its derivatives. Further work involving site-directed mutagenesis of the predicted residues will allow manipulation of AC activity using novel ligands, and crucial insights on the role of nitrosylation of these proteins in pathophysiological conditions.

Keywords

Adenylyl cyclase (AC) Cyclic adenosine monophosphate (cAMP) Protein modeling Ligand screening Nitric oxide (NO) Forskolin 

Notes

Acknowledgements

The work was supported by operating grants from Natural Sciences and Engineering Research Council (NSERC) to PC, Research Manitoba (RM) and Manitoba Chemosensory Biology (MCSB) catalyst grant to SD and University of Manitoba (Faculty of Science Interdisciplinary Grant) to JLS.

Compliance with ethical standards

Conflict of interest

All the authors have approved the final manuscript and declared that they have no conflict of interest.

Ethical standards

All methods performed in this study were in accordance with the ethical standards of the institution.

Supplementary material

11010_2018_3273_MOESM1_ESM.docx (244 kb)
Supplementary material 1 (DOCX 244 KB)

References

  1. 1.
    Smit MJ, Iyengar R (1998) Mammalian adenylyl cyclases. Adv Second Messenger Phosphoprot Res 32:1–21Google Scholar
  2. 2.
    Sassone-Corsi P (2012) The cyclic AMP pathway. Cold Spring Harb Perspect Biol.  https://doi.org/10.1101/cshperspect.a011148PubMedPubMedCentralGoogle Scholar
  3. 3.
    Santhosh KT, Elkhateeb O, Nolette N, Outbih O, Halayko AJ, Dakshinamurti S (2011) Milrinone attenuates thromboxane receptor-mediated hyperresponsiveness in hypoxic pulmonary arterial myocytes. Br J Pharmacol 163(6):1223–1236.  https://doi.org/10.1111/j.1476-5381.2011.01306.xCrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Krupinski J, Coussen F, Bakalyar HA, Tang WJ, Feinstein PG, Orth K, Slaughter C, Reed RR, Gilman AG (1989) Adenylyl cyclase amino acid sequence: possible channel- or transporter-like structure. Science 244(4912):1558–1564CrossRefPubMedGoogle Scholar
  5. 5.
    Sadana R, Dessauer CW (2009) Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies. Neurosignals 17(1):5–22.  https://doi.org/10.1159/000166277CrossRefPubMedGoogle Scholar
  6. 6.
    Mou TC, Gille A, Suryanarayana S, Richter M, Seifert R, Sprang SR (2006) Broad specificity of mammalian adenylyl cyclase for interaction with 2′,3′-substituted purine- and pyrimidine nucleotide inhibitors. Mol Pharmacol 70(3):878–886.  https://doi.org/10.1124/mol.106.026427CrossRefPubMedGoogle Scholar
  7. 7.
    Tesmer JJ, Sunahara RK, Johnson RA, Gosselin G, Gilman AG, Sprang SR (1999) Two-metal-Ion catalysis in adenylyl cyclase. Science 285(5428):756–760CrossRefPubMedGoogle Scholar
  8. 8.
    Nelson CP, Rainbow RD, Brignell JL, Perry MD, Willets JM, Davies NW, Standen NB, Challiss RA (2011) Principal role of adenylyl cyclase 6 in K(+) channel regulation and vasodilator signalling in vascular smooth muscle cells. Cardiovasc Res 91(4):694–702.  https://doi.org/10.1093/cvr/cvr137CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ishikawa Y (2003) Isoform-targeted regulation of cardiac adenylyl cyclase. J Cardiovasc Pharmacol 41(Suppl 1):S1–S4PubMedGoogle Scholar
  10. 10.
    Ishikawa Y, Sorota S, Kiuchi K, Shannon RP, Komamura K, Katsushika S, Vatner DE, Vatner SF, Homcy CJ (1994) Downregulation of adenylylcyclase types V and VI mRNA levels in pacing-induced heart failure in dogs. J Clin Invest 93(5):2224–2229.  https://doi.org/10.1172/JCI117219CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Okumura S, Takagi G, Kawabe J, Yang G, Lee MC, Hong C, Liu J, Vatner DE, Sadoshima J, Vatner SF, Ishikawa Y (2003) Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci USA 100(17):9986–9990.  https://doi.org/10.1073/pnas.1733772100CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Gao MH, Lai NC, Giamouridis D, Kim YC, Tan Z, Guo T, Dillmann WH, Suarez J, Hammond HK (2016) Cardiac-directed expression of adenylyl cyclase catalytic domain reverses cardiac dysfunction caused by sustained beta-adrenergic receptor stimulation. JACC 1(7):617–629.  https://doi.org/10.1016/j.jacbts.2016.08.004PubMedPubMedCentralGoogle Scholar
  13. 13.
    Liu X, Thangavel M, Sun SQ, Kaminsky J, Mahautmr P, Stitham J, Hwa J, Ostrom RS (2008) Adenylyl cyclase type 6 overexpression selectively enhances beta-adrenergic and prostacyclin receptor-mediated inhibition of cardiac fibroblast function because of colocalization in lipid rafts. Naunyn Schmiedebergs Arch Pharmacol 377(4–6):359–369.  https://doi.org/10.1007/s00210-007-0196-0CrossRefPubMedGoogle Scholar
  14. 14.
    McVey M, Hill J, Howlett A, Klein C (1999) Adenylyl cyclase, a coincidence detector for nitric oxide. J Biol Chem 274(27):18887–18892CrossRefPubMedGoogle Scholar
  15. 15.
    Chen SC, Huang B, Liu YC, Shyu KG, Lin PY, Wang DL (2008) Acute hypoxia enhances proteins’ S-nitrosylation in endothelial cells. Biochem Biophys Res Commun 377(4):1274–1278.  https://doi.org/10.1016/j.bbrc.2008.10.144CrossRefPubMedGoogle Scholar
  16. 16.
    Lorch SA, Foust R 3rd, Gow A, Arkovitz M, Salzman AL, Szabo C, Vayert B, Geffard M, Ischiropoulos H (2000) Immunohistochemical localization of protein 3-nitrotyrosine and S-nitrosocysteine in a murine model of inhaled nitric oxide therapy. Pediatr Res 47(6):798–805CrossRefPubMedGoogle Scholar
  17. 17.
    Qin Y, Dey A, Daaka Y (2013) Protein s-nitrosylation measurement. Methods Enzymol 522:409–425.  https://doi.org/10.1016/B978-0-12-407865-9.00019-4CrossRefPubMedGoogle Scholar
  18. 18.
    Gould N, Doulias PT, Tenopoulou M, Raju K, Ischiropoulos H (2013) Regulation of protein function and signaling by reversible cysteine S-nitrosylation. J Biol Chem 288(37):26473–26479.  https://doi.org/10.1074/jbc.R113.460261CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kokkola T, Savinainen JR, Monkkonen KS, Retamal MD, Laitinen JT (2005) S-nitrosothiols modulate G protein-coupled receptor signaling in a reversible and highly receptor-specific manner. BMC Cell Biol 6(1):21.  https://doi.org/10.1186/1471-2121-6-21CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Jeffrey Man HS, Tsui AK, Marsden PA (2014) Nitric oxide and hypoxia signaling. Vitam Horm 96:161–192.  https://doi.org/10.1016/B978-0-12-800254-4.00007-6CrossRefPubMedGoogle Scholar
  21. 21.
    Palmer LA, Kimberly D, Brown-Steinke K, Gunter S, Jyothikumar V, Forbes MS, Lewis SJ (2015) Hypoxia-induced changes in protein s-nitrosylation in female mouse brainstem. Am J Respir Cell Mol Biol 52(1):37–45.  https://doi.org/10.1165/rcmb.2013-0359OCCrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Breitkreuz M, Hamdani N (2015) A change of heart: oxidative stress in governing muscle function? Biophys Rev 7(3):321–341.  https://doi.org/10.1007/s12551-015-0175-5CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Marino SM, Gladyshev VN (2010) Structural analysis of cysteine S-nitrosylation: a modified acid-based motif and the emerging role of trans-nitrosylation. J Mol Biol 395(4):844–859.  https://doi.org/10.1016/j.jmb.2009.10.042CrossRefPubMedGoogle Scholar
  24. 24.
    Gaston BM, Carver J, Doctor A, Palmer LA (2003) S-nitrosylation signaling in cell biology. Mol Interv 3(5):253–263.  https://doi.org/10.1124/mi.3.5.253CrossRefPubMedGoogle Scholar
  25. 25.
    Chaki M, Kovacs I, Spannagl M, Lindermayr C (2014) Computational prediction of candidate proteins for S-nitrosylation in Arabidopsis thaliana. PLoS ONE 9(10):e110232.  https://doi.org/10.1371/journal.pone.0110232CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Shen MY, Sali A (2006) Statistical potential for assessment and prediction of protein structures. Protein Sci 15(11):2507–2524.  https://doi.org/10.1110/ps.062416606CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kumar M, Pydi SP, Sharma S, Singh TP, Kaur P (2014) Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach. J Mol Gr Model 51:104–112.  https://doi.org/10.1016/j.jmgm.2014.04.014CrossRefGoogle Scholar
  28. 28.
    Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26(2):283–291CrossRefGoogle Scholar
  29. 29.
    Xue Y, Liu Z, Gao X, Jin C, Wen L, Yao X, Ren J (2010) GPS-SNO: computational prediction of protein S-nitrosylation sites with a modified GPS algorithm. PLoS ONE 5(6):e11290.  https://doi.org/10.1371/journal.pone.0011290CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Lee TY, Chen YJ, Lu TC, Huang HD, Chen YJ (2011) SNOSite: exploiting maximal dependence decomposition to identify cysteine S-nitrosylation with substrate site specificity. PLoS ONE 6(7):e21849.  https://doi.org/10.1371/journal.pone.0021849CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Tannenbaum SR, White FM (2006) Regulation and specificity of S-nitrosylation and denitrosylation. ACS Chem Biol 1(10):615–618.  https://doi.org/10.1021/cb600439hCrossRefPubMedGoogle Scholar
  32. 32.
    Hess DT, Matsumoto A, Nudelman R, Stamler JS (2001) S-nitrosylation: spectrum and specificity. Nat Cell Biol 3(2):E46–E49.  https://doi.org/10.1038/35055152CrossRefPubMedGoogle Scholar
  33. 33.
    Stamler JS, Lamas S, Fang FC (2001) Nitrosylation. the prototypic redox-based signaling mechanism. Cell 106(6):675–683CrossRefPubMedGoogle Scholar
  34. 34.
    Tatee T, Narita A, Narita K, Izumi G, Takahira T, Sakurai M, Fujita A, Hosono M, Yamashita K, Enomoto K, Shiozawa A (1996) Forskolin derivatives. I. Synthesis, and cardiovascular and adenylate cyclase-stimulating activities of water-soluble forskolins. Chem Pharm Bull (Tokyo) 44(12):2274–2279CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Manitoba Chemosensory Biology (MCSB) Research GroupWinnipegCanada
  2. 2.Department of Oral BiologyUniversity of ManitobaWinnipegCanada
  3. 3.Department of ChemistryUniversity of ManitobaWinnipegCanada
  4. 4.Departments of Pediatrics, PhysiologyUniversity of ManitobaWinnipegCanada
  5. 5.Biology of Breathing, Children’s Hospital Research Institute of Manitoba (CHRIM)WinnipegCanada
  6. 6.Department of Oral Biology, and Manitoba Chemosensory Biology (MCSB) Research Group, D319University of ManitobaWinnipegCanada

Personalised recommendations